As Kv3.4 upregulation has been shown in humans and animal models (Angulo et al., 2004; Boscia et al., 2017) or following Aβ treatment (Pannaccione et al., 2007), future studies should focus on evaluating regional Kv3.4 mRNA and protein expression in different AD models and disease stages, including well before extensive amyloid plaque deposition. This evidence concerns the gene KCNC4 and Alzheimer disease.